Search research articles
Contact Us
Filters
Showing results (1041-1050 of 1,104) with videos related to
Page
of 111
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Maria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Cancer Research and Treatment
|
March 30, 2023
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
Yu Ri Kim, Jin Seok Kim, Won Seog Kim, et al.
Clinical Lymphoma & Myeloma
|
September 4, 2008
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma
Seok Jin Kim, Kihyun Kim, Byung Soo Kim, et al.
British Journal of Haematology
|
February 26, 2013
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
Yun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, et al.
Oncotarget
|
November 8, 2017
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, et al.
The Lancet. Oncology
|
April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Biomaterials
|
December 23, 2019
NFATc1+CD31+CD45- circulating multipotent stem cells derived from human endocardium and their therapeutic potential
Han-Mo Yang, Ju-Young Kim, Hyun-Jai Cho, et al.
Transfusion
|
December 10, 2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia
June-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, et al.
Biomed Research International
|
July 23, 2014
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study
Ki-Seong Eom, Seok Jin Kim, Je-Jung Lee, et al.
Haematologica
|
December 18, 2009
UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis
Hoi Soo Yoon, Hee-Jin Kim, Keon-Hee Yoo, et al.
Page
of 111
Search research articles
Search
Showing results (1041-1050 of 1,104) with videos related to
Sort By:
Page
of 111
Clinical Lymphoma, Myeloma & Leukemia
|
August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Maria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Cancer Research and Treatment
|
March 30, 2023
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
Yu Ri Kim, Jin Seok Kim, Won Seog Kim, et al.
Clinical Lymphoma & Myeloma
|
September 4, 2008
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma
Seok Jin Kim, Kihyun Kim, Byung Soo Kim, et al.
British Journal of Haematology
|
February 26, 2013
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
Yun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, et al.
Oncotarget
|
November 8, 2017
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, et al.
The Lancet. Oncology
|
April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Biomaterials
|
December 23, 2019
NFATc1+CD31+CD45- circulating multipotent stem cells derived from human endocardium and their therapeutic potential
Han-Mo Yang, Ju-Young Kim, Hyun-Jai Cho, et al.
Transfusion
|
December 10, 2013
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia
June-Won Cheong, Hyeoung-Joon Kim, Kyoo-Hyung Lee, et al.
Biomed Research International
|
July 23, 2014
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study
Ki-Seong Eom, Seok Jin Kim, Je-Jung Lee, et al.
Haematologica
|
December 18, 2009
UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis
Hoi Soo Yoon, Hee-Jin Kim, Keon-Hee Yoo, et al.
Page
of 111